Prescription compatibility mechanism research method based on effects of monarch drugs, ministerial drugs and adjuvant drugs in prescription

Abstract

The invention belongs to the technical field of research and analysis of traditional Chinese pharmacology, and particularly relates to a prescription compatibility mechanism research method based on effects of monarch drugs, ministerial drugs and adjuvant drugs in a prescription. According to the invention, the compatibility mechanism of the traditional Chinese medicine prescription is explained from the angle of the relationship between the chemical component change caused by monarch drugs, ministerial drugs, adjuvant drugs and the like in the prescription and the caused pharmacodynamic index change for the first time; compared with a traditional Chinese medicine prescription in which the compatibility mechanism is explained from the aspect of the properties of monarch drugs, ministerial drugs and adjuvant drugs, the composition is more distinct and clearer and is easy to understand. The operation of the invention overcomes the problem that the traditional Chinese medicine compatibility mechanism is too obscure or subjective assume or insufficient theoretical basis and the like due to concentrated description of component change, drug effect change, omics influence or action path change and the like in the current traditional Chinese medicine compatibility mechanism research.

Description

Technical Field

[0001] The invention belongs to the technical field of traditional Chinese medicine research and analysis, and specifically is a method for studying the prescription compatibility mechanism based on the effects of "main drug, minister drug and adjuvant drug" in the prescription. Background Art

[0002] Compatibility is the core of prescriptions. Prescription compatibility produces multiple synergistic active ingredients, which is the material basis for its efficacy. Reasonable compatibility can play a role in increasing efficacy and reducing toxicity. The earliest drug compatibility program was recorded in the "Shennong Bencao Jing". It is based on the "four qi and five flavors" principle, and follows the "seven emotions" and "monarch, minister, assistant and messenger" compatibility rules and the "principle, method, prescription and medicine" principle to formulate prescriptions for treatment. Modern compound prescription compatibility theory research focuses more on the intrinsic chemical substance basis of the compound, pharmacological and efficacy changes, etc., and the research tends to be digitized and visualized.

[0003] Some have studied the chemical composition of traditional Chinese medicine and found that the content of active ingredients has changed after compatibility, and new chemical components have been generated; some have also established PCOS mouse models around the changes in pharmacology and efficacy, and used pathological sections, network pharmacology, ELISA tests and other modern scientific technologies to analyze the mechanism of action of Fangfeng Tongsheng San. However, changes in chemical composition cannot fully represent changes in pharmacological effects, and the analysis of a single or several active ingredients cannot represent the overall changes after compatibility; the "single component-single target" pharmacological model is also difficult to reflect the overall nature of the traditional Chinese medicine compound, and cannot explain the mechanism of compound compatibility; due to the focus on explaining changes in composition, efficacy, omics effects or changes in action pathways, the mechanism of traditional Chinese medicine compatibility is either too obscure, or subjective, or lacks theoretical basis.

[0004] The present invention believes that the main medicine, ministerial medicine and adjuvant medicine in the Chinese medicine prescription should cause the drug efficacy to change through the chemical components they affect respectively. Therefore, the Chinese medicine prescription is split to explore the influence of the main medicine, ministerial medicine, adjuvant medicine on the chemical components and the pharmacology and efficacy respectively, and analyze the relationship between the two. The change of drug efficacy affected by the changes in the drug components of the main, ministerial, adjuvant and envoy of the prescription can be explained, so as to achieve the purpose of explaining the prescription compatibility mechanism. This is an important supplement to the traditional Chinese medicine prescription that explains the prescription compatibility from the perspective of Chinese medicine properties and dosage. Summary of the invention

[0005] In view of the above-mentioned technical problems, the present invention proposes a method for studying the prescription compatibility mechanism based on the role of "main drug, minister drug, and adjuvant drug" in the prescription. The present invention reflects the role of the main drug, minister drug, and adjuvant drug after the prescription is compatible, and can reveal that the prescription compatibility mechanism is "main drug mainly affects a certain index by regulating the content of a certain component; minister drug affects a certain index by regulating the content of a certain component; adjuvant drug affects a certain index by regulating the content of a certain index".

[0006] In order to achieve the above object, the present invention adopts the following technical solution.

[0007] A method for studying the compatibility mechanism of prescriptions based on the effects of "main drug, auxiliary drug, and adjuvant drug" in prescriptions, comprising the following steps:

[0008] Step 1, first determine the labeled active ingredients corresponding to the main drug, the auxiliary drug and the adjuvant drug in the prescription respectively;

[0009] Step 2, respectively determine the marker efficacy indexes of the main drug, the auxiliary drug and the adjuvant drug in the prescription;

[0010] Step 3: Based on the results of the correlation analysis between the contents of the labeled components corresponding to the main drug, auxiliary drug and adjuvant drug in the prescription and the labeled efficacy index, the compatibility mechanism of the prescription is explained.

[0011] Furthermore, step 1 is specifically as follows: 1.1: extracting the whole medicine group, Shaojun medicine group, Shaochen medicine group and Shaozhao medicine group of 10 prescriptions from different sources under certain conditions and studying their fingerprints; 1.2: identifying the common component structure of the whole medicine of the prescription; 1.3: comparing the common peak area differences between the whole medicine group of the prescription and the Shaojun medicine group, Shaochen medicine group and Shaozhao medicine group, and determining the marker drug components affected by the monarch drug, minister drug and adjuvant drug in the prescription respectively; 1.4: determining the peak areas of the marker drug components of the monarch drug, minister drug and adjuvant drug respectively according to the fingerprint results.

[0012] Furthermore, step 2 is specifically as follows: 2.1: extracting the whole medicine group, Shaojun medicine group, Shaochen medicine group and Shaozuo medicine group of the above batch of prescriptions according to the above conditions; 2.2: preparing a mouse model of the main efficacy of the prescription; 2.3: grouping and administering drugs according to blank group, model group, positive drug group, whole medicine group, Shaojun medicine group, Shaochen medicine group and Shaozuo medicine group; 2.4: measuring and calculating immunological and other microscopic indicators of each group after administration; 2.5: determining the marker efficacy indicators of the effects of the monarch medicine, minister medicine and adjuvant medicine in the prescription based on the difference analysis results of the efficacy indicators of the whole medicine group of the prescription and the Shaojun medicine group, Shaochen medicine group and Shaozuo medicine group.

[0013] Compared with the prior art, the beneficial effects of the present invention are as follows.

[0014] The present invention explains for the first time the compatibility mechanism of Chinese medicine prescriptions from the perspective of the relationship between the changes in chemical components induced by the monarch drug, minister drug, adjuvant drug, etc. in the Chinese medicine prescriptions and the changes in the efficacy indicators induced by them; compared with the traditional Chinese medicine prescriptions that explain the compatibility mechanism from the perspective of the medicinal properties of the monarch drug, minister drug, adjuvant drug, it is more vivid, clear and easy to understand.

[0015] The operation of the present invention overcomes the problems that the current research on the compatibility mechanism of traditional Chinese medicine is either too obscure, or subjective, or lacks theoretical basis, due to the focus on explaining changes in ingredients, changes in efficacy, omics effects, or changes in action pathways. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] Figure 1 These are the fingerprints of extracts from 10 sources of Yupingfeng Powder whole medicine group (Q1-Q10) (S1-S10, corresponding to Q1-Q10 respectively).

[0017] Figure 2 Fingerprints of extracts from 10 sources of Shaojun medicine group (Saposhnikovia divaricata-Atractylodes macrocephala, BF1-BF10) (S1-S10, corresponding to BF1-BF10 respectively).

[0018] Figure 3 Fingerprints of extracts from 10 source minority medicinal groups (Astragalus-Saposhnikovia divaricata, HF1-HF10) (S1-S10, corresponding to HF1-HF10, respectively).

[0019] Figure 4 Fingerprints of extracts from 10 minor adjuvant groups (Astragalus-Atractylodes macrocephala, HB1-HB10) (S1-S10, corresponding to HF1-HF10, respectively).

[0020] Figure 5 TIC diagram of Yupingfeng Powder and its various compatibility groups (negative ion mode, A. whole medicine, B. group with reduced monarch drug, C. group with reduced ministerial drug, D. group with reduced adjuvant drug).

[0021] Figure 6 This is the correlation heat map between the marker components affected by the monarch drug and the marker efficacy indicator IL2 affected.

[0022] Figure 7 This is a heat map of the correlation between the marker components affected by the monarch drug and the marker efficacy indicator IL4 affected.

[0023] Figure 8 It is a heat map of the correlation between the marker components affected by the adjuvant drugs and the marker efficacy index IGE affected by the adjuvant drugs.

[0024] Fig. 9 This is a heat map showing the correlation between the marker components affected by adjuvants and the marker efficacy indicator IL2 affected.

[0025] Fig.10 This is a heat map showing the correlation between the marker components affected by adjuvants and the marker efficacy indicator TGF-β. DETAILED DESCRIPTION

[0026] The following examples will help to understand the present invention, but these examples are only for illustrating the present invention, and the present invention is not limited to these contents. The operating methods in the examples are all conventional operating methods in the art.

[0027] Yupingfeng Powder comes from "Danxi's Heart Method" written by Zhu Zhenheng in the Yuan Dynasty. It is mainly composed of the main drug Huangqi, the auxiliary drug Baizhu, and the adjuvant drug Fangfeng. Huangqi is sweet and warm, enters the spleen and lung meridians to replenish qi and raise yang, and can also consolidate the exterior and stop sweating, promote diuresis and reduce swelling; Baizhu strengthens the spleen and replenishes qi, and combined with Huangqi to provide the source of qi and blood; Fangfeng moves the exterior and disperses wind evil, and can also help Huangqi and Baizhu to generate medicinal power. The combination of the three medicines has the function of strengthening the body, eliminating evil, and strengthening the exterior. Ke Yunbo of the Qing Dynasty recorded in "Ancient and Modern Famous Doctors' Prescriptions": "Husbands with Fangfeng's goodness in expelling wind, Huangqi to consolidate the exterior, then there is a defense outside, and Baizhu to consolidate the interior, then there is a basis inside, and the wind evil will go away and will not come back. It should be relied on like a screen and precious like jade." Modern clinical studies have found that Yupingfeng Powder has pharmacological effects such as anti-tumor, anti-inflammatory, antibacterial, antiviral, and immune regulation. It is widely used in the clinic to treat allergic rhinitis, bronchial asthma, pneumonia, chronic nephritis and other diseases. Combined with the literature and previous experimental studies, it has been confirmed that Yupingfeng Powder has significant efficacy in treating allergic rhinitis. Therefore, allergic rhinitis (AR) was selected as the pharmacological model for the study of the compatibility mechanism of Yupingfeng Powder.

[0028] A method for studying the compatibility mechanism of prescriptions based on the effects of "main drug, auxiliary drug, and adjuvant drug" in prescriptions, comprising the following steps:

[0029] Step 1: The present invention first determines the labeled active ingredients corresponding to the monarch drug, the minister drug and the adjuvant drug in Yupingfeng Powder, and the specific process is:

[0030] 1.1: The fingerprints of 10 whole medicines from different sources (Astragalus-Atractylodes-Saposhnikovia, Q1-Q10), Shaojun medicine group (Saposhnikovia-Atractylodes, BF1-BF10), Shaochen medicine group (Astragalus-Saposhnikovia, HF1-HF10) and Shaoshou medicine group (Astragalus-Atractylodes, HB1-HB10) were studied after extraction under certain conditions.

[0031] 1.2: Identify the common component structure of the whole medicine of Yupingfeng Powder.

[0032] 1.3: Compare the differences in the common peak areas between the whole medicine and the lesser monarch medicine group, lesser minister medicine group, and lesser adjuvant medicine group, and determine the marker drug components affected by the monarch medicine, minister medicine, and adjuvant medicine in Yupingfeng Powder respectively.

[0033] 1.4: Determine the peak areas of the marker drug components of the main drug, auxiliary drug and adjuvant drug according to the fingerprint results.

[0034] Step 2: respectively determine the marker efficacy indexes of the main drug, the ministerial drug and the adjuvant drug in Yupingfeng Powder, and the specific steps are as follows:

[0035] 2.1: The whole drug group (Q1-Q10), Shaojun drug group (Saposhnikovia divaricata-Atractylodes macrocephala, BF1-BF10), Shaochen drug group (Astragalus membranaceus-Saposhnikovia divaricata, HF1-HF10) and Shaosuo drug group (Astragalus membranaceus-Atractylodes macrocephala, HB1-HB10) of the above batches of Yupingfeng Powder were extracted according to the above conditions.

[0036] 2.2: Preparation of mouse allergic rhinitis model of the main medicinal effects of Yupingfeng Powder.

[0037] 2.3: The patients were divided into groups and dosed according to blank group, model group, positive drug group, full drug group (Q1-Q10), Shaojun drug group (Saposhnikovia divaricata-Atractylodes macrocephala, BF1-BF10), Shaochen drug group (Astragalus membranaceus-Saposhnikovia divaricata, HF1-HF10) and Shaoshou drug group (Astragalus membranaceus-Atractylodes macrocephala, HB1-HB10).

[0038] 2.4: Determine and calculate the immunological and other microscopic indicators of each group after administration.

[0039] 2.5: According to the difference analysis results of the efficacy indicators of the whole medicine and the lesser monarch medicine group, lesser minister medicine group and lesser adjuvant medicine group, the marker efficacy indicators of the monarch medicine, minister medicine and adjuvant medicine in Yupingfeng Powder are determined.

[0040] Step 3: Based on the results of correlation analysis between the contents of labeled components corresponding to the main drug, auxiliary drug and adjuvant drug in Yupingfeng Powder and the labeled efficacy indexes, the compatibility mechanism of Yupingfeng Powder is explained.

[0041] The research group used ovalbumin (OVA) intraperitoneal injection followed by nasal drip to replicate the mouse allergic rhinitis model. The behavioral scoring criteria are shown in Table 1. The results showed that the symptom score of the model group mice was 8.33±0.62 points, which was significantly higher than that of the blank group (1.27±0.46 points). The model group also had significantly more sneezing and nose scratching, and obvious runny nose, while the blank group mice did not show runny nose symptoms, indicating that the above modeling method is feasible.

[0042] Table 1. Grading standards for mouse symptom scores

[0043]

[0044]

[0045] Yupingfeng Powder is a compound of three Chinese medicines, Astragalus, Atractylodes, and Saposhnikovia, with complex chemical composition. In order to avoid the influence of the quality difference of medicinal materials and decoction pieces from different origins on the research of the material basis of drug efficacy, this experiment selected ten groups of medicinal materials from different origins and batches for grouping. Yupingfeng Powder whole medicine (Astragalus: Atractylodes: Saposhnikovia = 3:1:1, Q1-Q10) group, reduced monarch medicine (Atractylodes: Saposhnikovia = 1:1, BF1-BF10) group, reduced minister medicine (Astragalus: Saposhnikovia = 3:1, HF1-HF10) group, reduced adjuvant medicine (Astragalus: Atractylodes = 3:1, HB1-HB10) group, the medicinal materials selected in group 1 are all numbered 1, and those in group 2 are all numbered 2... (the origin of medicinal materials is shown in Table 2).

[0046] Table 2 Medicinal material origin and batch number information

[0047]

[0048]

[0049] The invention takes the treatment of allergic rhinitis in mice as the efficacy index, establishes a fingerprint spectrum, screens the common peaks of the whole medicine group and other groups, identifies the common peak components, analyzes the common peak area difference between the whole medicine group and other groups, and respectively screens the marked drug components affected by the monarch drug, minister drug and adjuvant drug; takes AR mice as the pathological model, adopts ELISA technology to evaluate the inflammation index of Yupingfeng powder group, monarch drug reduction group, minister drug reduction group and adjuvant drug reduction group, analyzes the efficacy difference between the whole medicine group and different compatibility groups, and screens the marked drug efficacy index affected by the monarch drug, minister drug and adjuvant drug; applies Pearson correlation analysis, respectively performs correlation analysis on the peak areas of the marked drug components affected by the monarch drug, minister drug and adjuvant drug in the whole medicine and the marked drug efficacy index of the whole medicine, clarifies the compatibility mechanism of Yupingfeng powder according to the analysis results, and provides a reference for the research on the modernization of traditional Chinese medicine.

[0050] The present invention first determines the research method of the marker drug components affected by the monarch drug, ministerial drug and adjuvant drug in Yupingfeng Powder. Specifically, the fingerprints of 10 batches of Yupingfeng Powder were determined by liquid chromatography, and the common peak components were identified by UPLC-Q-TOF HRMS-MS technology (the results are shown in Figure 1-Figure 4 , Table 3), and determine the common peak areas of the above groups.

[0051]

[0052]

[0053] The peak area results of the whole drug group and each compatibility group were imported into the statistical software SPSS Statistics 27 for T test analysis. The results showed that the peak area values ​​of each common peak were in line with the normal distribution and the data were reliable. The results are shown in Table 4. According to the sig value of ≤0.05 on both sides, the specific components were screened as marker components, and the marker drug components affecting the monarch drug in the whole drug were screened: sucrose, citric acid, calycosin-7-o-beta-d-glucoside, ononin, calycosin, formononetin, sec-o-glucosylhamaudol, astragaloside IV, astragaloside III, astragaloside II, astragaloside I I), Atractylon; the labeled drug components affected by the adjuvant drugs were screened out as: Atractylenolide III, Atractylenolide I, Atractylenolide II and Atractylon; the labeled drug components affected by the adjuvant drugs were screened out as: Cimicifugoside, Cimifugin, 5-O-methylvisammioside, Sec-O-Glucosylhamaudol.

[0054] Table 4 Common peak component difference analysis results ( * (p≤0.05)

[0055]

[0056]

[0057] The present invention determines the screening method of the marker efficacy index of the influence of the monarch drug, ministerial drug and adjuvant drug in the whole prescription. KM mice were randomly divided into 43 groups (n=10 in each group, half male and half female). The mice were divided into a positive drug group (P), a model group (M), a blank group (B) and a drug administration group (40 groups in total). The drug administration group includes 10 groups of full drug groups (Q1-Q10), 10 groups of reduced monarch drug groups (BF1-BF10), 10 groups of reduced ministerial drug groups (HF1-HF10), and 10 groups of reduced adjuvant drug groups (HB1-HB10). Except for the blank group, the remaining groups were intraperitoneally injected with ovalbumin suspension on days 0, 3 and 7 respectively; from the 15th day, the drug administration group was gavaged with the test solution extracted by the fingerprint research method, the positive drug was loratadine, and the blank group and the model group were given an equal volume of normal saline. After gavage for 1 hour, the ovalbumin suspension was nasally dripped to stimulate AR symptoms. Blood was collected 24 hours after the last stimulation, centrifuged, and the supernatant was collected; lung and spleen tissues were taken, ground with equal mass of physiological saline, centrifuged, and the supernatant was collected. The above liquids were operated according to the kit to determine the contents of IL2, IL4, IGE, IL9, IFN-γ, TGF-β, etc. in plasma and tissue fluid. The results are shown in Tables 5-10. As can be seen from the results, there were significant differences between the model groups and the blank groups for each index, indicating that the mice had allergic rhinitis and the model was successfully established. Most of the drug-administered groups were significantly different from the model group, indicating that each drug-administered group had a therapeutic effect on allergic rhinitis, and the effect of the Yupingfeng Powder full-drug group was better than that of other groups.

[0058] Table 5 IL2 index levels in each group (ng / mL)

[0059]

[0060]

[0061] Note: *Compared with the blank group, P < 0.05, #Compared with the model group, P < 0.05

[0062] Table 6 IL4 index levels in each group (ng / mL)

[0063]

[0064] Note: *Compared with the blank group, P < 0.05, #Compared with the model group, P < 0.05

[0065] Table 7 IGE index levels in each group (ng / mL)

[0066]

[0067]

[0068] Note: *Compared with the blank group, P < 0.05, #Compared with the model group, P < 0.05

[0069] Table 8 IL9 index levels in each group (ng / mL)

[0070]

[0071] Note: *Compared with the blank group, P < 0.05, #Compared with the model group, P < 0.05

[0072] Table 9 IFN-γ index levels in each group (ng / mL)

[0073]

[0074] Note: *Compared with the blank group, P < 0.05, #Compared with the model group, P < 0.05

[0075] Table 10 TGF-β index levels in each group (ng / mL)

[0076]

[0077]

[0078] Note: *Compared with the blank group, P < 0.05, #Compared with the model group, P < 0.05

[0079] The results of the efficacy indexes of the whole drug group and each combination group were imported into the statistical software SPSS Statistics 27 for T test analysis. The results showed that the results of each efficacy index were in accordance with the normal distribution and the data were reliable. The results are shown in Table 11. According to the sig value of both sides ≤ 0.05, IL2 and IL4 were determined as the marker efficacy indexes of the monarch drug; IGE was the marker efficacy index of the minister drug; IL2 and TGF-β were the marker efficacy indexes of the adjuvant drug.

[0080] Table 11 Statistical analysis results of marker efficacy indicators

[0081]

[0082] The present invention determines the role of the monarch drug in the compatibility through correlation analysis of the peak area of ​​the marked drug component affected by the monarch drug (Astragalus) in Yupingfeng Powder and the quantified result of the anti-allergic rhinitis efficacy index affected by the monarch drug; determines the role of the minister drug in the compatibility through correlation analysis of the peak area of ​​the marked drug component affected by the minister drug (Atractylodes macrocephala) in Yupingfeng Powder and the quantified result of the anti-allergic rhinitis efficacy index affected by the minister drug; determines the role of the adjuvant drug in the compatibility through correlation analysis of the peak area of ​​the marked drug component affected by the adjuvant drug (Saposhnikovia divaricata) in Yupingfeng Powder and the quantified result of the anti-allergic rhinitis efficacy index affected by the adjuvant drug, and the correlation analysis results are shown in Figure 6-10 .

[0083] The present invention determines the research method of the compatibility mechanism of Yupingfeng Powder for treating allergic rhinitis. That is, the correlation between the marked drug components and the marked drug efficacy indexes affected by the monarch drug, the minister drug, and the adjuvant drug is analyzed respectively, and the effects of the monarch drug, the minister drug, and the adjuvant drug in the traditional Chinese medicine prescription Yupingfeng Powder are explained respectively, and its compatibility mechanism is determined. The results are shown in FIG. Figure 6-Figure 10 ( * The correlation was significant at the 0.05 level). The results of correlation analysis showed that the correlation coefficients of citric acid, calycosin-7-o-beta-d-glucoside, ononin, calycosin and IL-2 were 0.66, 0.81, 0.68, and 0.66 (sig≤0.05), respectively; the correlation coefficients of calycosin-7-o-beta-d-glucoside, ononin, calycosin, and astragaloside I and IL-4 were -0.75, -0.87, -0.78, and -0.81 (sig≤0.05), respectively. The correlation coefficients of the drug components Atractylenolide I and Atractylenolide III of the auxiliary drug (Atractylenolide) with IGE were -0.7 and -0.67 (sig≤0.05), respectively. The correlation coefficients of the drug components Cimicifugoside and Sec-O-Glucosylhamaudol of the adjuvant drug (Saposhnikovia divaricata) with IL-2 were 0.82 and 0.66, respectively; the correlation coefficients of Cimicifugoside and 5-O-methylvisammioside with TGF-β were 0.78 and 0.7 (sig≤0.05), respectively.

[0084] Experimental results: A method for screening chemical components affected by the monarch drug, ministerial drug and adjuvant drug after the compatibility of Chinese medicine prescriptions was established, and the marker component indicators of the monarch drug, ministerial drug and adjuvant drug after the compatibility of Yupingfeng Powder were determined respectively: Marker drug components affected by the monarch drug: sucrose, citric acid, calycosin-7-o-beta-d-glucoside, ononin, calycosin, formononetin, sec-o-glutosylhamaudol, astragaloside IV, astragaloside III, astragaloside II, astragaloside I, atractylon. The marker drug components affected by the ministerial drugs were screened out as AtractylenolideⅢ, AtractylenolideⅠ, AtractylenolideⅡ and Atractylon. The marker drug components affected by the adjuvant drugs were screened out as Cimicifugoside, Cimifugin, 5-O-methylvisammioside and Sec-O-Glucosylhamaudol. The research method of marker efficacy indexes affected by the monarch drug, ministerial drug and adjuvant drugs after prescription compatibility was established, and the marker efficacy indexes affected by the monarch drug, ministerial drug and adjuvant drugs after the compatibility of Yupingfeng Powder were determined as follows: the marker efficacy indexes affected by the monarch drug were IL2 and IL4; the marker efficacy index affected by the ministerial drug was IGE; the marker efficacy indexes affected by the adjuvant drugs were IL2 and TGF-β.The research method of the compatibility mechanism of traditional Chinese medicine prescriptions was established, and the compatibility mechanism of Yupingfeng Powder was determined as follows: the main drug (Astragalus) increases the activity of citric acid, Calycosin-7-o-beta-d-glucoside, Ononin, Calycosin, Astragaloside I, The content of Atractylenolide I) regulates the IL-2 and IL-4 indexes in mice, thereby enhancing the effect of Yupingfeng Powder on treating allergic rhinitis; the assistant drug (Atractylenolide) downregulates the IGE index in mice by increasing the content of Atractylenolide I and Atractylenolide III, thereby enhancing the effect of Yupingfeng Powder on treating allergic rhinitis; the adjuvant (Saposhnikovia divaricata) upregulates the IL-2 and TGF-β indexes in mice by increasing the content of Cimicifugoside, Sec-O-Glucosylhamaudol and 5-O-methylvisammioside, thereby enhancing the effect of Yupingfeng Powder on treating allergic rhinitis.

[0085] In summary, the research method of the present invention can explain the compatibility mechanism of Yupingfeng Powder from the perspective of the influence of the changes in the chemical components of the prescription on the changes in the efficacy of the monarch drug, minister drug, and adjuvant drug. This method reflects the specific influence of the monarch drug, minister drug, and adjuvant drug in the prescription on the chemical components and efficacy of the prescription, and has positive significance for the study of the compatibility mechanism of other prescriptions. This compatibility mechanism research method combines the monarch, minister, adjuvant, and envoy theory in traditional Chinese medicine theory, the study of prescription decomposition, and the study of chemical components and specific efficacy in modern methods, which can explain the compatibility mechanism of traditional Chinese medicine compound prescriptions in an overall, comprehensive, systematic, and conditioning manner.

Claims

1. A method for studying the compatibility mechanism of prescriptions based on the effects of "main drug, auxiliary drug, and adjuvant drug" in prescriptions, characterized in that: The steps include: Step 1, first determine the labeled active ingredients corresponding to the main drug, the auxiliary drug and the adjuvant drug in the prescription respectively; Step 2, respectively determine the marker efficacy indexes of the main drug, the auxiliary drug and the adjuvant drug in the prescription; Step 3: Based on the results of the correlation analysis between the contents of the labeled components corresponding to the main drug, auxiliary drug and adjuvant drug in the prescription and the labeled efficacy index, the compatibility mechanism of the prescription is explained.

2. The method for studying the compatibility mechanism of prescriptions based on the effects of "main drug, auxiliary drug, and adjuvant drug" in prescriptions according to claim 1, characterized in that: The step 1 is specifically as follows: 1.1: extracting the whole medicine group, Shaojun medicine group, Shaochen medicine group and Shaozuo medicine group of 10 prescriptions from different sources under certain conditions and studying their fingerprints; 1.2: identifying the common component structure of the whole medicine of the prescription; 1.3: comparing the common peak area differences of the whole medicine group of the prescription with the Shaojun medicine group, Shaochen medicine group and Shaozuo medicine group, respectively, and determining the marker drug components affected by the monarch medicine, minister medicine and adjuvant medicine in the prescription; 1.4: Determine the peak areas of the marker drug components of the main drug, auxiliary drug and adjuvant drug according to the fingerprint results.

3. The method for studying the compatibility mechanism of prescriptions based on the effects of "main drug, auxiliary drug, and adjuvant drug" in prescriptions according to claim 1, characterized in that: The step 2 is specifically as follows: 2.1: extracting the whole medicine group, Shaojun medicine group, Shaochen medicine group and Shaozuo medicine group of the above batches of prescriptions according to the above conditions; 2.2: preparing a mouse model of the main efficacy of the prescription; 2.3: grouping and administering drugs according to blank group, model group, positive drug group, whole medicine group, Shaojun medicine group, Shaochen medicine group and Shaozuo medicine group; 2.4: measuring and calculating immunological and other microscopic indicators of each group after administration; 2.5: determining the marker efficacy indicators of the effects of the monarch medicine, minister medicine and adjuvant medicine in the prescription based on the difference analysis results of the efficacy indicators of the whole medicine group of the prescription and the Shaojun medicine group, Shaochen medicine group and Shaozuo medicine group.

Images